A Pilot Synaptic Vesicle Glycoprotein 2A (SV2A) PET Study to Evaluate the Effect of CT1812 Treatment on Synaptic Density in Participants with Mild to Moderate Alzheimer s Disease

Conditions

Alzheimer's Disease

Phase IB

What is the purpose of this trial?

CT1812 is a highly brain penetrant novel

sigma-2/PGRMC1 antagonist molecule that may prevent and displace the binding of Aβ

oligomers to neuronal synapses, thereby slowing the progression of Alzheimer’s disease. This is

an 8-month, placebo-controlled, Phase 1b single-center trial designed to evaluate the safety and

tolerability of CT1812 and to determine the effects of CT1812 on brain synaptic density in

Alzheimer’s disease. During the 169-day treatment period, participants will be randomized to

receive study drug (300 mg or 100 mg) or placebo that will be administered orally (66%

probability of receiving active study medication). Subjects will have up to 3 brain MRI scans, up

to 6 PET scans, and up to 2 lumbar punctures provided with study participation. Permits

concurrent treatment with cholinesterase inhibitors and/or memantine.

Visit the Alzheimer’s Disease Research Unit (ADRU) here – and link it to http://www.alzheimers.yale.edu 


  • Trial with
    Yale University School of Medicine
  • Start Date
    02/25/2018
  • End Date
    12/30/2019

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8348

Trial Image

For more information about this study, contact:

Carol Gunnoud

  • Last Updated
    05/25/2018
  • Study HIC
    #2000022248